APRI (Aprinoia Therapeutics) Total Liabilities: $105.44 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Total Liabilities?

Aprinoia Therapeutics APRI Total Liabilities is $105.44 Mil as of Dec. 2023.

Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $105.44 Mil.

Aprinoia Therapeutics's quarterly Total Liabilities increased from Dec. 2022 ($81.09 Mil) to Jun. 2023 ($96.41 Mil) and increased from Jun. 2023 ($96.41 Mil) to Dec. 2023 ($105.44 Mil).

Aprinoia Therapeutics's annual Total Liabilities increased from Dec. 2021 ($61.45 Mil) to Dec. 2022 ($81.09 Mil) and increased from Dec. 2022 ($81.09 Mil) to Dec. 2023 ($105.44 Mil).

Aprinoia Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Total Liabilities Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Liabilities
61.45 81.09 105.44

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities 61.45 0.00 81.09 96.41 105.44

Aprinoia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aprinoia Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.351+(0.208+65.876
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=105.44

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=4.946--100.489
=105.44

Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.351+(0.208+65.876
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=105.44

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=4.946--100.489
=105.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $105.44 Mil mean?
Aprinoia Therapeutics (APRI) has a Total Liabilities of $105.44 Mil as of Dec. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Total Liabilities too high?
Aprinoia Therapeutics' current Total Liabilities is $105.44 Mil.
How does Aprinoia Therapeutics' Total Liabilities compare to ?
Aprinoia Therapeutics' Total Liabilities of $105.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Total Liabilities is $105.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Total Liabilities of $105.44 Mil. The current Total Liabilities is $105.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Total Liabilities is $105.44 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.